ULURU Inc. Announces Strategic Joint Development Agreement With BioProgress plc
May 04 2006 - 9:00AM
PR Newswire (US)
DALLAS, May 4 /PRNewswire-FirstCall/ -- ULURU Inc. (OTC:ULURE)
(BULLETIN BOARD: ULURE) ("ULURU") today announced that it has
signed a joint strategic development agreement with the specialty
pharmaceutical and healthcare company, BioProgress plc
(NASDAQ:BPRG). The companies will initially work together to
develop an anti-emetic product for the relief of nausea, using a
combination of BioProgress' film technology and ULURU's Oradisc(TM)
drug delivery technology. This relationship will then go on to
develop further therapeutic products. ULURU is focused on the
development of a portfolio of wound management, plastic surgery and
oral care products to provide patients and consumers improved
clinical outcomes through controlled delivery. ULURU's OraDisc(TM)
technology is an innovative erodible film technology that sticks to
mucous membranes that allows sustained release of actives into the
systemic circulation over a period of several hours. The new
products are expected to resemble BioProgress' in-the-mouth range
of films strips, which dissolve instantly, releasing the embedded
active ingredients. However, by adding the Oradisc(TM) technology
to these films, the resulting products will not only be fast
acting, but will also offer sustained release of actives over
several hours. These new products will therefore have properties
that neither technology could achieve on its own. Patients with
nausea are often unable to take tablets effectively, so an
in-the-mouth instant release anti-emetic offers a good solution to
treat acute nausea and the OraDisc technology provides a longer
term solution to the problem. This is a therapeutic area with a
large unmet need. BioProgress have a large amount of in-house
expertise in this area and ULURU has significant experience in the
development of film technology through FDA approval. Richard
Trevillion, CEO of BioProgress, said: "We are delighted to be
entering a strategic partnership with ULURU. The technologies from
both companies are complementary and can work in combination to
create products with both instant release and sustained release
characteristics. This approach has the potential to create real
therapeutic value and enhance the effectiveness of medicines."
Kerry Gray, President and CEO of ULURU Inc. stated, "This
partnership is exciting for both companies as we can access the
development strengths and resources of both groups. Our ability to
combine instant release with sustained delivery over an extended
period has the potential to create considerable value. We will be
applying proven technologies to existing medicines with the
objective of dramatically improving the resultant profile." About
ULURU Inc.: ULURU Inc. is an emerging specialty pharmaceutical
company focused on the development of a portfolio of wound
management, plastic surgery and oral care products to provide
patients and consumers improved clinical outcomes through
controlled delivery utilizing its innovative transmucosal delivery
system and Hydrogel Nanoparticle Aggregate technology. About
BioProgress plc: BioProgress plc is an innovative specialty
pharmaceutical and healthcare business based around its platform
technologies in polymer and film systems. Listed on London's AIM in
May 2003 and on US NASDAQ in October 2004, the company has over 80
patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several
global companies. As a virtually integrated business, BioProgress
has acquired sales and marketing resources within Europe and the US
as a launch mechanism for its own pharmaceutical products. The
business continues to develop innovative delivery mechanisms using
its XGEL(TM) polymer technology, replacing the need to use
animal-derived gelatine in pharmaceutical and healthcare products.
For further information please go to http://www.bioprogress.com/ .
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended, and that involve risks and uncertainties,
including but not limited to statements made relating to the
establishment of strategic joint development agreements and the
risks and uncertainties associated with product development
activities. These statements are subject to numerous risks,
including but not limited to the risks detailed in the Company's
Annual Report on Form 10-K for the year ended December 31, 2004,
Quarterly Report on Form 10-Q for the quarter ended September 30,
2005 and other reports filed by us with the Securities and Exchange
Commission. Contact: Company Kerry P. Gray President & CEO
Terry K. Wallberg Vice President & CFO (214) 905-5145
DATASOURCE: ULURU Inc. CONTACT: Kerry P. Gray, President & CEO,
or Terry K. Wallberg, Vice President & CFO, both of ULURU INC.,
+1-214-905-5145 Web site: http://www.uluruinc.com/
http://www.bioprogress.com/
Copyright
Bioprogress (NASDAQ:BPRG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bioprogress (NASDAQ:BPRG)
Historical Stock Chart
From Oct 2023 to Oct 2024